Kamada Ltd KMDA 深 滬
已收盤 02-06 16:00:00 美东时间
8.21
+0.190
+2.37%
華盛通- 最 高8.23
- 今 開8.03
- 成交量 3.05万股
- 最 低 8.02
- 昨 收 8.02
- 總市值 4.74亿
- 52周最高 8.88
- 市盈率 靜 32.83
- 換手率 0.05%
- 52周最低 5.54
- 委 比 -10.36%
- 總股本 5768.14万
- 歷史最高 17.75
- 量 比 0.50
- 振 幅 2.62%
- 歷史最低 2.82
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
Alvotech announced positive top-line results from a pharmacokinetic (PK) study for AVT80, a biosimilar candidate to Entyvio (vedolizumab). The AVT80-GL-P01 study met all primary endpoints, demonstrating PK similarity, safety, tolerability, and immunogenicity profiles in healthy adult participants. This milestone supports the development and regulatory submissions of AVT16 and AVT80, biosimilar candidates for Entyvio.
02-05 08:00
Kamada forecasts double-digit profitable growth in 2026
Kamada forecasts 2026 revenues of $200M – $205M, compared to estimates of 200.7M and adjusted EBITDA of $50M –$53M. The 2026 outlook implies year-over-year growth of 13% in revenues and 23% in adjuste...
01-08 00:49
Kamada Sees FY2026 Sales $200.000M-$205.000M vs $200.598M Est
Kamada (NASDAQ:KMDA) sees FY2026 sales of $200.000 million-$205.000 million vs $200.598 million analyst estimate.
01-07 20:21
Kamada Affirms FY2025 Sales Guidance of $178.000M-$182.000M vs $181.137M Est
Kamada (NASDAQ:KMDA) affirms FY2025 sales outlook from $178.000 million-$182.000 million to $178.000 million-$182.000 million vs $181.137 million estimate.
01-07 20:21
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
Kamada Ltd. forecasts 2026 revenues of $200-$205 million and adjusted EBITDA of $50-$53 million, reflecting 13% and 23% increases respectively from 2025 mid-point guidance. Growth is driven by organic expansion of its commercial product portfolio, including U.S. sales and ex-U.S. sales of key products like KAMRAB® and GLASSIA®. The company also prioritizes M&A and business development to enhance its product portfolio and long-term growth. Kamada ...
01-07 12:00
Kamada Wins $10–$14 Million Extension of Canadian Plasma-Product Tender
Kamada ( ($IL:KMDA) ) has shared an announcement. On December 18, 2025, Kamada ...
2025-12-18 20:27
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Kamada Reiterates its 2025 Revenue Guidance of $178M-$182M Vs. Consensus Of $180.66M, And Adjusted EBITDA of $40M-$44M
Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026
2025-12-08 20:08
Kamada To Discontinue Phase 3 InnovAATe Trial As Prespecified Interim Futility Analysis Shows The Trial Of Inhaled AAT For Alpha-1 Antitrypsin Deficiency Is Unlikely To Demonstrate A Statistically Significant Benefit In Its Primary Endpoint
Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA, its AAT-IV
2025-12-08 20:06
Kamada Affirms FY2025 Sales Guidance of $178.000M-$182.000M vs $180.659M Est
Kamada (NASDAQ:KMDA) affirms FY2025 sales outlook from $178.000 million-$182.000 million to $178.000 million-$182.000 million vs $180.659 million estimate.
2025-11-10 20:24
